Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2788750 | 0.96 | MAP3K5 (0.93) | MAP3K5MEN1TSHRKMT2ATRPA1 | |
| SCHEMBL2810841 | 0.96 | MAP3K5 (0.93) | MAP3K5MEN1TSHRKMT2ATRPA1 | |
| SCHEMBL2787335 | 0.95 | MAP3K5 (0.91) | MAP3K5MEN1TSHRKMT2ATRPA1 | |
| SCHEMBL2787745 | 0.95 | MAP3K5 (0.91) | MAP3K5MEN1TSHRKMT2ATRPA1 | |
| SCHEMBL3022906 | 0.93 | MAP3K5 (0.86) | MAP3K5MEN1TSHRKMT2ATRPA1 | |
| SCHEMBL3022901 | 0.93 | MAP3K5 (0.86) | MAP3K5MEN1TSHRKMT2ATRPA1 | |
| SCHEMBL3020554 | 0.90 | MAP3K5 (0.81) | MAP3K5MEN1TSHRKMT2ATRPA1 | |
| SCHEMBL12317257 | 0.90 | MAP3K5 (0.81) | MAP3K5MEN1TSHRKMT2ATRPA1 | |
| SCHEMBL2790472 | 0.89 | MAP3K5 (0.80) | MAP3K5MEN1TSHRKMT2ATRPA1 | |
| Formic Acid SCHEMBL2790328 | 0.88 | MAP3K5 (0.78) | MAP3K5MEN1TSHRKMT2ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373577-A1 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| EP-4351723-A2 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4351626-A2 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| US-20230390268-A1 | METHOD FOR TREATING VIRAL INFECTIONS USING ASK1 INHIBITORS | MCMASTER UNIVERSITY (CA) | 2023-12-07 | — | — | US | claimed |
| EP-4274600-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION | Acceleron Pharma Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| US-20230226146-A1 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | ACCELERON PHARMA INC. | 2023-07-20 | — | — | US | claimed |
| US-20230190875-A1 | SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHODS FOR TREATING PULMONARY HYPERTENSION | ACCELERON PHARMA INC. | 2023-06-22 | — | — | US | claimed |
| US-20230174620-A1 | ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION | ACCELERON PHARMA INC. | 2023-06-08 | — | — | US | claimed |
| EP-4168037-A1 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | Acceleron Pharma Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| CN-115989035-A | ACTRII proteins for the treatment of Pulmonary Arterial Hypertension (PAH) | 阿塞勒隆制药公司 | 2023-04-18 | — | — | CN | claimed |
| EP-4073101-A1 | SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHODS FOR TREATING PULMONARY HYPERTENSION | Acceleron Pharma Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| WO-2022150590-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION | ACCELERON PHARMA INC. (US) | 2022-07-14 | — | — | WO | claimed |
| US-20220175758-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | Coherus Biosciences, Inc. | 2022-06-09 | — | — | US | claimed |
| US-20200397798-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | AKARNA THERAPEUTICS, LTD. (GB) | 2020-12-24 | — | — | US | claimed |
| US-20200390858-A1 | Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases | NGM BIOPHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | claimed |
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | claimed |
| US-8263595-B2 | Triazolopyridine compounds and their use as ask inhibitors | MERCK SERONO SA (CH) | 2012-09-11 | — | — | US | claimed |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | claimed |
| EP-2181112-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | Merck Serono S.A. (CH) | 2010-05-05 | — | — | EP | claimed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390268-A1 | METHOD FOR TREATING VIRAL INFECTIONS USING ASK1 INHIBITORS | IRAK1, EIF2AK2, ZC3HAV1 | MAP3K5 17/4885MEN1 1759/4885TSHR 3606/4885 |
| US-20220175758-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | SLC10A1, LIPC, FABP1 | MAP3K5 2394/4885MEN1 4105/4885TSHR 3213/4885 |
| US-20200397798-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | DPP4, TLR1, SLC5A1 | MAP3K5 427/4885MEN1 4466/4885TSHR 2349/4885 |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MAP3K5, MAPKAPK5, MAP3K9 | MAP3K5 1/4885MEN1 3192/4885TSHR 2204/4885 |
| US-20230174620-A1 | ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION | ACTR3, ACTR5, ACTR2 | MAP3K5 1368/4885MEN1 4664/4885TSHR 2644/4885 |
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MAP3K5, MAPKAPK5, MAP3K9 | MAP3K5 1/4885MEN1 3192/4885TSHR 2204/4885 |
| US-20230226146-A1 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | EDNRB, MYLK, VASP | MAP3K5 1019/4885MEN1 4475/4885TSHR 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.